Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ESRRA | P11474 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2094131 | 0.84 | RXRA (0.33) | PPARGRXRARXRBRXRGNFKB1 | |
| SCHEMBL26165535 | 0.81 | CTSS (0.40) | MAOBMRGPRX4NOTUM | |
| SCHEMBL535974 | 0.79 | ADRA2A (0.39) | PPARGRXRARXRBRXRGNFKB1 | |
| SCHEMBL18415682 | 0.79 | ALDH1A1 (0.45) | RXRARXRBRXRGGAAALDH1A1 | |
| SCHEMBL28774590 | 0.78 | TDP1 (0.44) | RXRARXRBRXRGGAAALDH1A1 | |
| SCHEMBL9881101 | 0.77 | ALDH1A1 (0.42) | LMNAGAAALDH1A1TDP1 | |
| SCHEMBL2095726 | 0.75 | GAA (0.41) | RXRARXRBRXRGGAAALDH1A1 | |
| SCHEMBL1685381 | 0.75 | LTA4H (0.46) | PPARGRXRARXRBRXRGMRGPRX4 | |
| SCHEMBL5003721 | 0.75 | RXRA (0.49) | PPARGRXRARXRBRXRGMRGPRX4 | |
| SCHEMBL8799400 | 0.75 | MAOB (0.39) | PPARGRXRARXRBRXRGNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| US-11695158-B2 | Nonaqueous electrolyte, capacitor device using same, and carboxylic acid ester compound used in same | MU IONIC SOLUTIONS CORPORATION (JP) | 2023-07-04 | — | — | US | disclosed |
| US-20210320334-A1 | NONAQUEOUS ELECTROLYTE, CAPACITOR DEVICE USING SAME, AND CARBOXYLIC ACID ESTER COMPOUND USED IN SAME | MU IONIC SOLUTIONS CORPORATION (JP) | 2021-10-14 | — | — | US | disclosed |
| US-20190198928-A1 | NONAQUEOUS ELECTROLYTE, CAPACITOR DEVICE USING SAME, AND CARBOXYLIC ACID ESTER COMPOUND USED IN SAME | UBE INDUSTRIES, LTD. (JP) | 2019-06-27 | — | — | US | disclosed |
| EP-3086396-B1 | NONAQUEOUS ELECTROLYTE WITH CARBOXYLIC ACID ESTER COMPOUND AND ENERGY STORAGE DEVICE USING SAME | UBE INDUSTRIES (JP) | 2019-06-05 | — | — | EP | disclosed |
| US-10263285-B2 | Nonaqueous electrolyte, capacitor device using same, and carboxylic acid ester compound used in same | UBE INDUSTRIES, LTD. (JP) | 2019-04-16 | — | — | US | disclosed |
| US-20180166746-A1 | NONAQUEOUS ELECTROLYTE, CAPACITOR DEVICE USING SAME, AND CARBOXYLIC ACID ESTER COMPOUND USED IN SAME | UBE INDUSTRIES, LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-2701230-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION, ELECTRICITY STORAGE DEVICE USING THE SAME, AND TRIFLUOROMETHYLBENZENE COMPOUND | UBE INDUSTRIES (JP) | 2016-11-23 | — | — | EP | disclosed |
| EP-3086396-A1 | NONAQUEOUS ELECTROLYTE, CAPACITOR DEVICE USING SAME, AND CARBOXYLIC ACID ESTER COMPOUND USED IN SAME | UBE Industries, Ltd. (JP) | 2016-10-26 | — | — | EP | disclosed |
| US-9472828-B2 | Nonaqueous electrolyte solution, electricity storage device using same, and trifluoromethylbenzene compound | UBE INDUSTRIES, LTD. (JP) | 2016-10-18 | — | — | US | disclosed |
| US-7659416-B2 | Monomolecular conductive complex, conductive self-assembled film and assembly of electrode composed of metal and semiconductor making use of the same | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20090036698-A1 | Monomolecular Conductive Complex, Conductive Self-Assembled Film and Assembly of Electrode Composed of Metal and Semiconductor Making Use of the Same | TOKYO INSTITUTE OF TECHNOLOGY | 2009-02-05 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1862453-A1 | MONOMOLECULAR CONDUCTIVE COMPLEX, CONDUCTIVE SELF-ASSEMBLED FILM AND ASSEMBLY OF ELECTRODE COMPOSED OF METAL AND SEMICONDUCTOR MAKING USE OF THE SAME | Tokyo Institute of Technology (JP) | 2007-12-05 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | PPARG 856/4885RXRA 143/4885RXRB 117/4885 |
| US-20090036698-A1 | Monomolecular Conductive Complex, Conductive Self-Assembled Film and Assembly of Electrode Composed of Metal and Semiconductor Making Use of the Same | CNTN1, GAP43, AP3M1 | PPARG 4783/4885RXRA 4474/4885RXRB 4276/4885 |
| US-20180166746-A1 | NONAQUEOUS ELECTROLYTE, CAPACITOR DEVICE USING SAME, AND CARBOXYLIC ACID ESTER COMPOUND USED IN SAME | SLC9A2, VDAC1, SCO2 | PPARG 2542/4885RXRA 1224/4885RXRB 1629/4885 |
| US-20190198928-A1 | NONAQUEOUS ELECTROLYTE, CAPACITOR DEVICE USING SAME, AND CARBOXYLIC ACID ESTER COMPOUND USED IN SAME | SLC9A2, VDAC1, SCO2 | PPARG 2542/4885RXRA 1224/4885RXRB 1629/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | PPARG 457/4885RXRA 179/4885RXRB 138/4885 |
| US-11695158-B2 | Nonaqueous electrolyte, capacitor device using same, and carboxylic acid ester compound used in same | SLC9A2, VDAC1, SCO2 | PPARG 2542/4885RXRA 1224/4885RXRB 1629/4885 |
| US-10263285-B2 | Nonaqueous electrolyte, capacitor device using same, and carboxylic acid ester compound used in same | SLC9A2, VDAC1, SCO2 | PPARG 2542/4885RXRA 1224/4885RXRB 1629/4885 |
| US-20210320334-A1 | NONAQUEOUS ELECTROLYTE, CAPACITOR DEVICE USING SAME, AND CARBOXYLIC ACID ESTER COMPOUND USED IN SAME | SLC9A2, VDAC1, SCO2 | PPARG 2542/4885RXRA 1224/4885RXRB 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.